medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (1)


Acute Variceal Bleeding: Does Octreotide Improve Outcomes in Patients with Different Functional Hepatic Reserve?

Monreal-Robles R, Cortez-Hernández CA, González-González JA, Abraldes JG, Bosques-Padilla FJ, Silva-Ramos HN, García-Flores JA, Maldonado-Garza HJ

Idioma: Ingles.
Referencias bibliográficas: 30
Paginas: 125-133
Archivo PDF: 166.19 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. D'Amico G, De Franchis R, Cooperative Study G. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.

  2. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-9.

  3. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.

  4. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-32.

  5. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-38.

  6. Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, Austin A, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015; 64: 1680-704.

  7. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-52.

  8. Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, Kwon SO, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100: 631-5.

  9. Seo YS, Park SY, Kim MY, Kim JH, Park JY, Yim HJ, Jang BK, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014; 60: 954-63.

  10. Wells M, Chande N, Adams P, Beaton M, Levstik M, Boyce E, Mrkobrada M. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35: 1267-78.

  11. Abraldes JG, Villanueva C, Banares R, Aracil C, Catalina MV, Garci APJC, Bosch J, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008; 48: 229-36.

  12. Flores-Rendon AR, Gonzalez-Gonzalez JA, Garcia-Compean D, Maldonado-Garza HJ, Garza-Galindo AA. Model for end stage of liver disease (MELD) is better than the Child- Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. Ann Hepatol 2008; 7: 230-34.

  13. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005; 42 Suppl: S100-107.

  14. Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-Arbol L, Salcedo M, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 609-15.

  15. Villanueva C, Ortiz J, Sabat M, Gallego A, Torras X, Soriano G, Sainz S, et al. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Hepatology 1999; 30: 384-9.

  16. Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, Leung VK, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346: 1666-9.

  17. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, Hochain P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555-60.

  18. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350: 1495-9.

  19. Lo GH, Chen WC, Wang HM, Lin CK, Chan HH, Tsai WL, Cheng LC, et al. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut 2009; 58: 1275-80.

  20. Dai C, Liu WX, Jiang M, Sun MJ. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World J Gastroenterol 2015; 21: 2534-41.

  21. Berreta J, Kociak D, Romero G, Balducci A, Amaya R, Argonz J. [Endoscopic versus endoscopic plus octreotide treatment for acute variceal bleeding. Benefit according to severity at admission]. Acta Gastroenterol Latinoam 2013; 43: 89-97.

  22. Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am J Gastroenterol 2000; 95: 768-71.

  23. Vilas-Boas WW, Ribeiro-Oliveira A, Jr., Pereira RM, Ribeiro Rda C, Almeida J, Nadu AP, Simoes, Silva AC, et al. Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 2009; 15: 2512-19.

  24. Goral V, Atayan Y, Kaplan A. The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor alpha? Hepatogastroenterology 2011; 58: 943-8.

  25. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, Bach J, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol 2005; 42: 195-201.

  26. Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, Sauerbruch T, Spengler U. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2011; 23: 1218-25.

  27. Fukui H, Tsujita S, Matsumoto M, Kitano H, Hoppou K, Morimura M, Takaya A, et al. Endotoxemia in chronic hepatitis and cirrhosis: Epiphenomenon or of pathological relevence? In: Blum H, Bode C, Bode JC, Sartor RB (editors). Gut and the Liver. Dordrecht, Boston, London: Kluwer Academic Publishers; 1998.

  28. Kumar A, Jha SK, Mittal VV, Sharma P, Sharma BC, Sarin SK. Addition of Somatostatin After Successful Endoscopic Variceal Ligation Does not Prevent Early Rebleeding in Comparison to Placebo: A Double Blind Randomized Controlled Trial. J Clin Exp Hepatol 2015; 5: 204-12.

  29. Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, Keough A, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 2014; 146: 412-419.e413.

  30. Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP, et al. Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol 2016. In press.




2020     |     www.medigraphic.com